264 related articles for article (PubMed ID: 37379367)
1. Targeting CCR7-PI3Kγ overcomes resistance to tyrosine kinase inhibitors in ALK-rearranged lymphoma.
Mastini C; Campisi M; Patrucco E; Mura G; Ferreira A; Costa C; Ambrogio C; Germena G; Martinengo C; Peola S; Mota I; Vissio E; Molinaro L; Arigoni M; Olivero M; Calogero R; Prokoph N; Tabbò F; Shoji B; Brugieres L; Geoerger B; Turner SD; Cuesta-Mateos C; D'Aliberti D; Mologni L; Piazza R; Gambacorti-Passerini C; Inghirami GG; Chiono V; Kamm RD; Hirsch E; Koch R; Weinstock DM; Aster JC; Voena C; Chiarle R
Sci Transl Med; 2023 Jun; 15(702):eabo3826. PubMed ID: 37379367
[TBL] [Abstract][Full Text] [Related]
2. Tyrosine phosphatases regulate resistance to ALK inhibitors in ALK+ anaplastic large cell lymphoma.
Karaca Atabay E; Mecca C; Wang Q; Ambrogio C; Mota I; Prokoph N; Mura G; Martinengo C; Patrucco E; Leonardi G; Hossa J; Pich A; Mologni L; Gambacorti-Passerini C; Brugières L; Geoerger B; Turner SD; Voena C; Cheong TC; Chiarle R
Blood; 2022 Feb; 139(5):717-731. PubMed ID: 34657149
[TBL] [Abstract][Full Text] [Related]
3. Activating mutations in ALK kinase domain confer resistance to structurally unrelated ALK inhibitors in NPM-ALK-positive anaplastic large-cell lymphoma.
Zdzalik D; Dymek B; Grygielewicz P; Gunerka P; Bujak A; Lamparska-Przybysz M; Wieczorek M; Dzwonek K
J Cancer Res Clin Oncol; 2014 Apr; 140(4):589-98. PubMed ID: 24509625
[TBL] [Abstract][Full Text] [Related]
4. Activation of IGF-1R pathway and NPM-ALK G1269A mutation confer resistance to crizotinib treatment in NPM-ALK positive lymphoma.
Li Y; Wang K; Song N; Hou K; Che X; Zhou Y; Liu Y; Zhang J
Invest New Drugs; 2020 Jun; 38(3):599-609. PubMed ID: 31177400
[TBL] [Abstract][Full Text] [Related]
5. Patient-derived xenograft models of ALK+ ALCL reveal preclinical promise for therapy with brigatinib.
Prokoph N; Matthews JD; Trigg RM; Montes-Mojarro IA; Burke GAA; Fend F; Merkel O; Kenner L; Geoerger B; Johnston R; Murray MJ; Riguad C; Brugières L; Turner SD
Br J Haematol; 2023 Sep; 202(5):985-994. PubMed ID: 37357529
[TBL] [Abstract][Full Text] [Related]
6. Crizotinib in Combination with Everolimus Synergistically Inhibits Proliferation of Anaplastic Lymphoma Kinase‒Positive Anaplastic Large Cell Lymphoma.
Xu W; Kim JW; Jung WJ; Koh Y; Yoon SS
Cancer Res Treat; 2018 Apr; 50(2):599-613. PubMed ID: 28675026
[TBL] [Abstract][Full Text] [Related]
7. IL10RA modulates crizotinib sensitivity in NPM1-ALK+ anaplastic large cell lymphoma.
Prokoph N; Probst NA; Lee LC; Monahan JM; Matthews JD; Liang HC; Bahnsen K; Montes-Mojarro IA; Karaca-Atabay E; Sharma GG; Malik V; Larose H; Forde SD; Ducray SP; Lobello C; Wang Q; Luan SL; Pospíšilová Š; Gambacorti-Passerini C; Burke GAA; Pervez S; Attarbaschi A; Janíková A; Pacquement H; Landman-Parker J; Lambilliotte A; Schleiermacher G; Klapper W; Jauch R; Woessmann W; Vassal G; Kenner L; Merkel O; Mologni L; Chiarle R; Brugières L; Geoerger B; Barbieri I; Turner SD
Blood; 2020 Oct; 136(14):1657-1669. PubMed ID: 32573700
[TBL] [Abstract][Full Text] [Related]
8. Cytoreductive antitumor activity of PF-2341066, a novel inhibitor of anaplastic lymphoma kinase and c-Met, in experimental models of anaplastic large-cell lymphoma.
Christensen JG; Zou HY; Arango ME; Li Q; Lee JH; McDonnell SR; Yamazaki S; Alton GR; Mroczkowski B; Los G
Mol Cancer Ther; 2007 Dec; 6(12 Pt 1):3314-22. PubMed ID: 18089725
[TBL] [Abstract][Full Text] [Related]
9. P-glycoprotein Mediates Ceritinib Resistance in Anaplastic Lymphoma Kinase-rearranged Non-small Cell Lung Cancer.
Katayama R; Sakashita T; Yanagitani N; Ninomiya H; Horiike A; Friboulet L; Gainor JF; Motoi N; Dobashi A; Sakata S; Tambo Y; Kitazono S; Sato S; Koike S; John Iafrate A; Mino-Kenudson M; Ishikawa Y; Shaw AT; Engelman JA; Takeuchi K; Nishio M; Fujita N
EBioMedicine; 2016 Jan; 3():54-66. PubMed ID: 26870817
[TBL] [Abstract][Full Text] [Related]
10. ALK kinase domain mutations in primary anaplastic large cell lymphoma: consequences on NPM-ALK activity and sensitivity to tyrosine kinase inhibitors.
Lovisa F; Cozza G; Cristiani A; Cuzzolin A; Albiero A; Mussolin L; Pillon M; Moro S; Basso G; Rosolen A; Bonvini P
PLoS One; 2015; 10(4):e0121378. PubMed ID: 25874976
[TBL] [Abstract][Full Text] [Related]
11. Prognostic significance and therapeutic potential of the activation of anaplastic lymphoma kinase/protein kinase B/mammalian target of rapamycin signaling pathway in anaplastic large cell lymphoma.
Gao J; Yin M; Zhu Y; Gu L; Zhang Y; Li Q; Jia C; Ma Z
BMC Cancer; 2013 Oct; 13():471. PubMed ID: 24112608
[TBL] [Abstract][Full Text] [Related]
12. Iruplinalkib (WX‑0593), a novel ALK/ROS1 inhibitor, overcomes crizotinib resistance in preclinical models for non-small cell lung cancer.
Yang Y; Zheng Q; Wang X; Zhao S; Huang W; Jia L; Ma C; Liu S; Zhang Y; Xin Q; Sun Y; Zheng S
Invest New Drugs; 2023 Apr; 41(2):254-266. PubMed ID: 37036582
[TBL] [Abstract][Full Text] [Related]
13. Targeting autophagy enhances the anti-tumoral action of crizotinib in ALK-positive anaplastic large cell lymphoma.
Mitou G; Frentzel J; Desquesnes A; Le Gonidec S; AlSaati T; Beau I; Lamant L; Meggetto F; Espinos E; Codogno P; Brousset P; Giuriato S
Oncotarget; 2015 Oct; 6(30):30149-64. PubMed ID: 26338968
[TBL] [Abstract][Full Text] [Related]
14. STAT1 is phosphorylated and downregulated by the oncogenic tyrosine kinase NPM-ALK in ALK-positive anaplastic large-cell lymphoma.
Wu C; Molavi O; Zhang H; Gupta N; Alshareef A; Bone KM; Gopal K; Wu F; Lewis JT; Douglas DN; Kneteman NM; Lai R
Blood; 2015 Jul; 126(3):336-45. PubMed ID: 25921060
[TBL] [Abstract][Full Text] [Related]
15. Treatment Sequencing in Patients with Anaplastic Lymphoma Kinase-Positive Non-Small Cell Lung Cancer in Japan: A Real-World Observational Study.
Goto Y; Yamamoto N; Masters ET; Kikkawa H; Mardekian J; Wiltshire R; Togo K; Ohe Y
Adv Ther; 2020 Jul; 37(7):3311-3323. PubMed ID: 32472430
[TBL] [Abstract][Full Text] [Related]
16. Evidence Suggesting That Discontinuous Dosing of ALK Kinase Inhibitors May Prolong Control of ALK+ Tumors.
Amin AD; Rajan SS; Liang WS; Pongtornpipat P; Groysman MJ; Tapia EO; Peters TL; Cuyugan L; Adkins J; Rimsza LM; Lussier YA; Puvvada SD; Schatz JH
Cancer Res; 2015 Jul; 75(14):2916-27. PubMed ID: 26018086
[TBL] [Abstract][Full Text] [Related]
17. Cytokine receptor signaling is required for the survival of ALK- anaplastic large cell lymphoma, even in the presence of JAK1/STAT3 mutations.
Chen J; Zhang Y; Petrus MN; Xiao W; Nicolae A; Raffeld M; Pittaluga S; Bamford RN; Nakagawa M; Ouyang ST; Epstein AL; Kadin ME; Del Mistro A; Woessner R; Jaffe ES; Waldmann TA
Proc Natl Acad Sci U S A; 2017 Apr; 114(15):3975-3980. PubMed ID: 28356514
[TBL] [Abstract][Full Text] [Related]
18. Nucleophosmin-anaplastic lymphoma kinase: the ultimate oncogene and therapeutic target.
Werner MT; Zhao C; Zhang Q; Wasik MA
Blood; 2017 Feb; 129(7):823-831. PubMed ID: 27879258
[TBL] [Abstract][Full Text] [Related]
19. ALK-dependent control of hypoxia-inducible factors mediates tumor growth and metastasis.
Martinengo C; Poggio T; Menotti M; Scalzo MS; Mastini C; Ambrogio C; Pellegrino E; Riera L; Piva R; Ribatti D; Pastorino F; Perri P; Ponzoni M; Wang Q; Voena C; Chiarle R
Cancer Res; 2014 Nov; 74(21):6094-106. PubMed ID: 25193384
[TBL] [Abstract][Full Text] [Related]
20. Crizotinib-resistant NPM-ALK mutants confer differential sensitivity to unrelated Alk inhibitors.
Ceccon M; Mologni L; Bisson W; Scapozza L; Gambacorti-Passerini C
Mol Cancer Res; 2013 Feb; 11(2):122-32. PubMed ID: 23239810
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
